Dacarbazine citrate

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 581192

CAS#: 64038-56-8 (citrate)

Description: Dacarbazine citrate belongs to the group of medicines called alkylating agents. It is used to treat cancer of the lymph system and malignant melanoma (a type of skin cancer). It may also be used to treat other kinds of cancer, Dacarbazine citrate interferes with the growth of cancer cells, which are eventually destroyed. Dacarbazine citrate is used in certain patients with the following medical conditions: Cancer of the islet cells (a part of the pancreas) Soft tissue sarcomas (a cancer of the muscles, tendons, vessels that carry blood or lymph, joints, and fat).

Chemical Structure

img
Dacarbazine citrate
CAS# 64038-56-8 (citrate)
Instruction

Theoretical Analysis

MedKoo Cat#: 581192
Name: Dacarbazine citrate
CAS#: 64038-56-8 (citrate)
Chemical Formula: C12H18N6O8
Exact Mass: 0.00
Molecular Weight: 374.310
Elemental Analysis: C, 38.51; H, 4.85; N, 22.45; O, 34.19

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 4342-03-4 (free base)   17925-90-5 (HCl)   64038-56-8 (citrate)  

Synonym: Dacarbazine citrate; Dacarbazine citrate; DTIC citrate; UNII-9UYU348NIF;

IUPAC/Chemical Name: Imidazole-4-carboxamide, 5-(3,3-dimethyl-1-triazeno)-, citrate

InChi Key: UKLSKIDEWQXQJZ-ASTDGNLGSA-N

InChi Code: InChI=1S/C6H10N6O.C6H8O7/c1-12(2)11-10-6-4(5(7)13)8-3-9-6;7-3(8)1-6(13,5(11)12)2-4(9)10/h3H,1-2H3,(H2,7,13)(H,8,9);13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/b11-10+;

SMILES Code: O=C(C1=C(/N=N/N(C)C)NC=N1)N.OC(C(O)=O)(CC(O)=O)CC(O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 374.31 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Di Martino A, Sedlarik V. Amphiphilic chitosan-grafted-functionalized polylactic acid based nanoparticles as a delivery system for doxorubicin and temozolomide co-therapy. Int J Pharm. 2014 Oct 20;474(1-2):134-45. doi: 10.1016/j.ijpharm.2014.08.014. Epub 2014 Aug 12. PubMed PMID: 25124059.

2: Stark P, Steinmetz A, Hefetz M, Hardoff R. Misleading Ga-67 uptake in a patient with Hodgkin's disease, mediastinal deviation, and pulmonary compression. Clin Nucl Med. 2002 Dec;27(12):898-9. PubMed PMID: 12607876.

3: St-Coeur PD, Poitras JJ, Cuperlovic-Culf M, Touaibia M, Morin P Jr. Investigating a signature of temozolomide resistance in GBM cell lines using metabolomics. J Neurooncol. 2015 Oct;125(1):91-102. doi: 10.1007/s11060-015-1899-6. Epub 2015 Aug 28. PubMed PMID: 26311249.

4: Buesa JM, Gracia M, Valle M, Estrada E, Hidalgo OF, Lacave AJ. Phase I trial of intermittent high-dose dacarbazine. Cancer Treat Rep. 1984 Mar;68(3):499-504. PubMed PMID: 6704980.

5: Lunn G, Sansone EB. Reductive destruction of dacarbazine, procarbazine hydrochloride, isoniazid, and iproniazid. Am J Hosp Pharm. 1987 Nov;44(11):2519-24. PubMed PMID: 3687991.

6: Saba HI, Cruse CW, Wells KE, Klein CJ, Reintgen DS. Adjuvant chemotherapy in malignant melanoma using dacarbazine, carmustine, cisplatin, and tamoxifen: a University of South Florida and H. Lee Moffitt Melanoma Center Study. Ann Plast Surg. 1992 Jan;28(1):60-4. PubMed PMID: 1642408.

7: Ha CS, Choe JG, Kong JS, Allen PK, Oh YK, Cox JD, Edmund E. Agreement rates among single photon emission computed tomography using gallium-67, computed axial tomography and lymphangiography for Hodgkin disease and correlation of image findings with clinical outcome. Cancer. 2000 Sep 15;89(6):1371-9. PubMed PMID: 11002233.

8: Re A, Ferrari S, Frata P, Pizzocaro C, Crippa C, Tucci A, Facchetti F, Grazioli L, Magrini SM, Rossi G. Late computed tomography scan response improvement and gallium scintigraphy evaluation as on-treatment prognostic parameters to tailor treatment intensity in patients with Hodgkin's lymphoma. A prospective phase II study. Ann Oncol. 2008 May;19(5):951-7. doi: 10.1093/annonc/mdm596. Epub 2008 Jan 21. PubMed PMID: 18209012.

9: Saba HI, Cruse CW, Wells KE, Klein CJ, Reintgen DS. Treatment of stage IV malignant melanoma with dacarbazine, carmustine, cisplatin, and tamoxifen regimens: a University of South Florida and H. Lee Moffitt Melanoma Center Study. Ann Plast Surg. 1992 Jan;28(1):65-9. PubMed PMID: 1642409.

10: Saita C, Yajima K, Iwasaki Y, Oohinata R, Ishiyama S, Yuu K. [Multidisciplinary Treatment for a Patient with Primary Malignant Melanoma Arising from the Stomach]. Gan To Kagaku Ryoho. 2015 Jul;42(7):859-61. Japanese. PubMed PMID: 26197750.

11: Fukunaga T, Soejima H, Sugamura K, Kojima S, Sugiyama S, Sakamoto T, Yoshimura M, Tanoue T, Kageshita T, Ono T, Ogawa H. Acute myocardial infarction induced by cisplatin-based combination chemotherapy for malignant melanoma: a case report. J Cardiol. 2006 Apr;47(4):191-5. PubMed PMID: 16637253.

12: Herman K, Szabó L, Leopold LF, Chiş V, Leopold N. In situ laser-induced photochemical silver substrate synthesis and sequential SERS detection in a flow cell. Anal Bioanal Chem. 2011 May;400(3):815-20. doi: 10.1007/s00216-011-4798-5. Epub 2011 Feb 26. PubMed PMID: 21359570.

13: Zinzani PL, Zompatori M, Bendandi M, Battista G, Fanti S, Barbieri E, Gherlinzoni F, Rimondi MR, Frezza G, Pisi P, Merla E, Gozzetti A, Canini R, Monetti N, Babini L, Tura S. Monitoring bulky mediastinal disease with gallium-67, CT-scan and magnetic resonance imaging in Hodgkin's disease and high-grade non-Hodgkin's lymphoma. Leuk Lymphoma. 1996 Jun;22(1-2):131-5. PubMed PMID: 8724540.

14: Liang P, Shi H, Zhu W, Gui Q, Xu Y, Meng J, Guo X, Gong Z, Chen H. Silver nanoparticles enhance the sensitivity of temozolomide on human glioma cells. Oncotarget. 2017 Jan 31;8(5):7533-7539. doi: 10.18632/oncotarget.13503. PubMed PMID: 27893419; PubMed Central PMCID: PMC5352340.